Crossmark

Patient-reported use of pancreatic enzyme replacement treatment (PERT) in pancreatic cancer in New Zealand and Australia: a cross-sectional survey study

Crossref DOI link: https://doi.org/10.1007/s00520-024-08604-1

Published Online: 2024-06-03

Published Print: 2024-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Landers, Amanda https://orcid.org/0000-0002-7385-3739
Brown, Helen

Al Ruheili, Juhaina

Russell, Kylie

McKenzie, Clare

Agar, Meera R.

Yenson, Vanessa M. https://orcid.org/0000-0002-7112-0785
Clarke, Kate

Windsor, John
Funding

Funding for this research was provided by:

Health Research Council of New Zealand (21/906)

Canterbury Medical Research Foundation (GIA 2021-03)

University of Otago
License Information

Text and Data Mining valid from 2024-06-01

Version of Record valid from 2024-06-03
More Information

Article History

Received: 5 November 2023

Accepted: 24 May 2024

First Online: 3 June 2024

Declarations

:

: NZ Ethics was approved by University of Otago Human Ethics Committee (H21/069). AU Ethics was ratified by University of Technology Sydney Human Ethics Committee (ETH21-6203).

: Consent to participate in the study was obtained electronically through the information sheet at the commencement of the survey. The participant could only proceed onto the survey if they agreed to the conditions of consent. All data was collected anonymously.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below